CLINICAL TRIAL

Investigating the Role of Serotonin in the Mechanism of Action of Psilocybin in Patients With Major Depressive Disorder

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: ClinicalTrials.gov
Date: 2025-05-14
Source: ClinicalTrials.gov
DOI: Unavailable
PubMed: Unavailable

Authors

Icahn School of Medicine at Mount Sinai

Watch author

Derived topics and classifications

psilocybin Depression Mechanism of Action Receptor Pharmacology Other

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

PRISMatic: A Phase 1b Randomized, Double-Armed, Parallel-Group, Placebo-Controlled Trial of Psilocybin Efficacy With or Without Pimavanserin PretreatmentClinicalTrials.gov · 2026-07-21 Chronic pain education: past, present, and future of psychedelics for the management of chronic painPain Medicine · 2024-12-10 Psychedelics and Psychotherapy: Is the Whole Greater than the Sum of its Parts?Clinical Pharmacology & Therapeutics · 2023-10-05 CSF galanin and noradrenaline downregulation by psilocybin therapy in major depressive disorderNeuropsychopharmacology · 2026-07-07 Harnessing neuroplasticity with psychoplastogens: the essential role of psychotherapy in psychedelic treatment optimizationFrontiers in Psychiatry · 2025-04-08 Could psilocin rescue chronic, stress-accelerated, transcriptional aging in brain?UKnowledge (University of Kentucky) · 2025-03-04 Psilocybin, Depression, and Synaptogenesis: Insights into the Field’s Past, Present, and FutureGeorgetown Scientific Research Journal · 2023-10-10 Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism.Expert opinion on drug discovery · 2022-10-01